Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity
详细信息 查看全文
- 作者：Noah M. Hahn ; M.D.a ; b ; 1 ; Beatrice S. Knudsen ; M.D. ; Ph.D.c ; 1 ; Siamak Daneshmand ; M.D.d ; e ; Michael O. Koch ; M.D.a ; Richard Bihrle ; M.D.a ; Richard S. Foster ; M.D.a ; Thomas A. Gardner ; M.D.a ; Liang Cheng ; M.D.a ; Ziyue Liu ; Ph.D.a ; Timothy Breen ; Ph.D.a ; Mark T. Fleming ; M.D.f ; Raymond Lance ; M.D.g ; Christopher L. Corless ; M.D. ; Ph.D.d ; Ajjai S. Alva ; M.D.h ; i ; Steven S. Shen ; M.D. ; Ph.D.j ; Fangjin Huang ; M.S.c ; Arkadiusz Gertych ; Ph.D.c ; Gary E. Gallick ; Ph.D.k ; Jayati Mallick ; M.D.c ; Christopher Ryan ; M.D.d ; Matthew D. Galsky ; M.D.l ; Seth P. Lerner ; M.D.h ; Edwin M. Posadas ; M.D.c ; Guru Sonpavde ; M.D.m ; gsonpavde@uabmc.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Urothelial carcinoma ; Bladder ; Neoadjuvant therapy ; Protein kinase inhibitors ; Src-family kinases ; Dasatinib ; Translational medical research
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：34
- 期：1
- 页码：4.e11-4.e17
- 全文大小：408 K
文摘
- •
Dasatinib, a Src inhibitor, was feasible as neoadjuvant therapy for bladder cancer.
- •
Overall, significant Src pathway inhibition was seen in tumor tissue.
- •
Cell proliferation and apoptosis were unaltered overall.
- •
Src inhibition appears ineffective in unselected bladder cancer patients.
- •
The neoadjuvant trial paradigm may complement drug development.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |